NCT00610610 - Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

December 31, 2002

Study Completion Date

December 31, 2002

Conditions

Fibromyalgia Syndrome

Interventions

DRUG

Paroxetine CR

Those in the active treatment group will receive doses of Paxil CR in the following manner: week 1: 12.5 mg per day, week 2: 25 mg per day, week 3: 37.5 mg per day, wk 4: 50 mg per day and week 5: 62.5 mg per day.

DRUG

Placebo

Same shape Placebo

Trial Locations (2)

19107

Thomas Jefferson University, Philadelphia

27705

Duke University Medical Center, Durham